A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese PatientsWithMetastatic Colorectal Cancer (BIX Study)

作者：Hamamoto Yasuo^*; Yamaguchi Tatsuro; Nishina Tomohiro; Yamazaki Kentaro; Ura Takashi; Nakajima Takako; Goto Ayumu; Shimada Ken; Nakayama Norisuke; Sakamoto Junichi; Yamada Yasuhide

来源：Oncologist, 2014, 19(11): 1131-1132.

DOI：10.1634/theoncologist.2014-0159

Background. Capecitabine is used mainly with oxaliplatin to treat metastatic colorectal cancer (mCRC). Results from capecitabine plus irinotecan (XELIRI) with or without bevacizumab (BV) have been reported in Europe but not in Japan. Consequently, the safety and efficacy of XELIRI plus BV in Japanese patients with mCRC were assessed in a single-arm phase II study. %26lt;br%26gt;Methods. Eligible patients had had prior chemotherapy containing BV for mCRC and wild-type or heterozygous UGT1A1. Therapy in each 21-day treatment cycle consisted of capecitabine (800 mg/m(2) twice daily on days 1-15), irinotecan (200 mg/m(2) on day 1), and BV (7.5 mg/kg on day 1). The primary endpoint was dose-limiting toxicity in phase I and progression-free survival (PFS) in phase II. Results. A total of 34 patients (6 in phase I, 28 in phase II) were enrolled from May 2010 to June 2011. Baseline characteristics included a median age of 60 years (range: 22-74 years) for 24 men and 10 women. No dose-limiting toxicities appeared in phase I. Median PFS was 240 days (95% confidence interval: 179-311 days). Overall response rate was 18.1%, and the disease-control ratewas90.9%. The incidence of adverse events frequently associated with irinotecan and capecitabine were neutropenia (any grade, 55.9%; grade 3 or 4, 11.8%), diarrhea (any grade, 50%; grade 3 or 4, 5.9%), and hand-foot syndrome (any grade, 61.8%; grade 3 or 4, 5.9%). %26lt;br%26gt;Conclusion. Our results suggest that XELIRI plus BV is well tolerated and effective as a second-line treatment formCRC in Japanese patients. This regimen could be especially

• 出版日期2014-11